Wugen to Participate in Upcoming April Investor Conferences

ST. LOUIS & SAN DIEGO--(BUSINESS WIRE)--Wugen, Inc., a clinical-stage biotechnology company developing a pipeline of off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced that management will participate in two upcoming virtual investor conferences in April:

• 21st Annual Needham Virtual Healthcare Conference
  Format: Panel titled “Company Perspectives: Companies Discussing Key Features and Differentiators in the NK Cellular Therapeutics Space”
  Date/Time: Thursday, April 14, 2022 at 11:00 a.m. ET
  Location: Virtual

• Chardan’s 6th Annual Genetic Medicines and Cell Therapy Manufacturing Summit
  Format: Fireside Chat
  Date/Time: Tuesday, April 26, 2022 at 9 a.m. ET
  Location: Virtual

About Wugen

Wugen, Inc., is a clinical-stage biotechnology company developing the next generation of off-the-shelf memory natural killer (NK) and CAR-T cell therapies for cancer. Wugen is leveraging its proprietary Moneta^TM platform and deep genomic engineering expertise to pioneer a new class of memory NK cell therapies to treat hematological and solid tumor malignancies. For more information, please visit www.wugen.com.

Investor:
Elsie Yau, Stern Investor Relations, Inc.
212-698-8700
elsie.yau@sternir.com